☆ 4.8 Article

LRPPRC facilitates tumor progression and immune evasion through upregulation of m(6)A modification of PD-L1 mRNA in hepatocellular carcinoma

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

RM2Target: a comprehensive database for targets of writers, erasers and readers of RNA modifications

Xiaoqiong Bao et al.

Summary: RNA modification is a dynamic and reversible process regulated by writers, erasers and readers (WERs). Abnormal changes of WERs disrupt RNA modification homeostasis, leading to dysregulation of RNA metabolism and diseases. The RM2Target database stores WER-target associations for nine RNA modifications, providing extensive annotations for target genes and facilitating downstream functional and mechanistic studies in RNA modification research.

NUCLEIC ACIDS RESEARCH (2023)

Add to Collection

Article Gastroenterology & Hepatology

Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments

Yutaka Kurebayashi et al.

Summary: HCC can be categorized into four distinct immunovascular subtypes (IH/AS, IM/AM, IL/AG, and IL/AL) reflecting the reciprocal interaction between the antitumor immune microenvironment and tumor angiogenesis. The different subtypes are associated with decreasing lymphocytic infiltration, increasing angiogenic factor expression, and VETC/MTM positivity. IL/AG subtype is characterized by CTNNB1 mutation and Wnt/beta-catenin pathway activation, while IL/AL subtype is not associated with increased lymphocyte infiltration or angiogenic factor expression.

HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma

Yeming Yang et al.

Summary: Type 2 diabetes is closely related to non-alcoholic fatty liver disease, which can lead to liver damage. Researchers have developed a new mouse model of diabetes-related non-alcoholic fatty liver disease, which can be used to study the development of liver disease and epigenetic regulation mechanisms.

MOLECULAR THERAPY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny

Jianpeng Sheng et al.

Summary: This study identified different functional units of HCC TME using imaging mass cytometry, with a focus on the importance of Kupffer cells in immunotherapy for HCC.

GUT (2022)

Add to Collection

Article Biochemistry & Molecular Biology

METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer

Weijun Wan et al.

Summary: The study found that METTL3 can post-transcriptionally upregulate PD-L1 expression in an m(6)A-IGF2BP3-dependent manner to promote stabilization of PD-L1 mRNA. This may have important implications for new and efficient therapeutic strategies in tumor immunotherapy.

MOLECULAR CANCER (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells

Jia Xiong et al.

Summary: The lactylation-driven METTL3-mediated RNA m(6)A modification plays an important role in promoting the immunosuppressive capacity of tumor-infiltrating myeloid cells (TIMs).

MOLECULAR CELL (2022)

Add to Collection

Review Gastroenterology & Hepatology

Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy

Nguyen H. Tran et al.

Summary: Hepatocellular carcinoma is a global health challenge, and liver transplantation is the best long-term treatment option. Locoregional methods for downstaging have limitations, while systemic treatments show potential for downstaging before transplantation. Assessment, endpoints, and clinical trial designs are critical considerations.

HEPATOLOGY (2022)

Add to Collection

Article Immunology

The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma

Dan Li et al.

Summary: RNA modification of m6A/m5C/m1A plays a crucial role in the prognosis and immune microenvironment of hepatocellular carcinoma (HCC). The cluster subgroup and risk model of m6A/m5C/m1A regulated genes are associated with the poor prognosis and immune microenvironment in HCC.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Relationship between M6A methylation regulator and prognosis in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

Deliang Huang et al.

Summary: This study aimed to investigate the possible function of ceRNA networks and m6A regulators in patients with TACE HCC and to predict their treatment response.

HELIYON (2022)

Add to Collection

Article Biochemistry & Molecular Biology

ALKBH5/MAP3K8 axis regulates PD-L1+macrophage infiltration and promotes hepatocellular carcinoma progression

Yu You et al.

Summary: ALKBH5 is highly expressed in hepatocellular carcinoma (HCC) and is associated with worse prognosis. It promotes the proliferation and metastasis of HCC cells and recruits macrophages through the ALKBH5/MAP3K8 axis, thus promoting HCC growth and metastasis.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2022)

Add to Collection

Article Oncology

Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240

Baek-Yeol Ryoo et al.

Summary: Pembrolizumab preserved health-related quality of life during treatment for advanced hepatocellular carcinoma. The positive benefit/risk profile of pembrolizumab in a second-line treatment setting for patients who previously received sorafenib is supported by these findings in combination with efficacy and safety results.

CANCER (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Cell Biology

LncRNA SNHG17 interacts with LRPPRC to stabilize c-Myc protein and promote G1/S transition and cell proliferation

Jin-Yu Liu et al.

Summary: The study reveals that SNHG17 interacts with LRPPRC to enhance c-Myc expression, accelerate G1/S transition and cell proliferation, promoting tumor growth. High levels of SNHG17 or LRPPRC are associated with lower survival rates in HCC patients.

CELL DEATH & DISEASE (2021)

Add to Collection

Article Cell Biology

m6A regulator-mediated RNA methylation modification patterns are involved in immune microenvironment regulation of periodontitis

Xiaoqi Zhang et al.

Summary: Through the study of 310 periodontitis samples, it was found that m6A modification plays a crucial role in the immune microenvironment of periodontitis, involving regulation of immune cell infiltration, immune reaction gene sets, HLA genes, and more. Some m6A regulators were found to be dysregulated, and a signature of 15 m6A regulators can effectively distinguish periodontitis from control samples.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)

Add to Collection

Article Biochemical Research Methods

Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma

Yin Li et al.

Summary: This study systematically evaluated the m(6)A modification features in LUAD, revealing aberrant expression of m(6)A regulators linked to patient survival and various biological pathways, including immune-related pathways. A scoring tool named m6Sig was established, showing positive correlation with PD-L1 expression and therapeutic advantages in LUAD patients receiving anti-PD-L1 immunotherapy.

BRIEFINGS IN BIOINFORMATICS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model

Yue Zhang et al.

Summary: The study constructed an integrative m6A model based on A-HCC subtyping and mechanism exploration, identifying high/low-risk subtypes of A-HCC patients. The high-risk subtype showed poor prognosis, immunosuppression, and activation of pathways related to tumorigenesis and proliferation.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)

Add to Collection

Article Oncology

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

TIMER2.0 for analysis of tumor-infiltrating immune cells

Taiwen Li et al.

NUCLEIC ACIDS RESEARCH (2020)

Add to Collection

Article Biochemistry & Molecular Biology

LRPPRC sustains Yap-P27-mediated cell ploidy and P62-HDAC6-mediated autophagy maturation and suppresses genome instability and hepatocellular carcinomas

Wenjiao Li et al.

ONCOGENE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A Five-Gene Signature Based on Stromal/Immune Scores in the Tumor Microenvironment and Its Clinical Implications for Liver Cancer

Xichun Liu et al.

DNA AND CELL BIOLOGY (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Landscape of N6-Methyladenosine Modification Patterns in Human Ameloblastoma

Xing Niu et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells

Dali Han et al.

NATURE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis

Zefang Tang et al.

NUCLEIC ACIDS RESEARCH (2019)

Add to Collection

Article Gastroenterology & Hepatology

Epidemiology and Management of Hepatocellular Carcinoma

Laura Kulik et al.

GASTROENTEROLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3

Tian Lan et al.

MOLECULAR CANCER (2019)

Add to Collection

© Peeref 2019-2024. All rights reserved.